The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The changing role of chemotherapy in lymphoma and the value of novel immunotherapies
Ranjit Nair, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the changing role of chemotherapy in the treatment of patients with Hodgkin and non-Hodgkin lymphoma (HL; NHL). Whilst chemotherapy has typically been the standard of care (SOC), novel immunotherapies, including CAR-T cell therapy, bispecifics, and antibody-drug conjugates (ADCs), have provided valuable alternatives for patients with relapsed/refractory (R/R) disease. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
